This inventor holds 25 USPTO granted patents and 11 published patent applications and 2 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Sepracor, Inc., Scripps Research Institute, University of Florida Research Foundation Inc.. Active years: 2003-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Northborough, MA (US) (2003 - 2010)
- Palm Beach Gardens, FL (US) (2009 - 2023)
Company Filing History:
11 out of 322 
7 out of 1,209 
3 out of 3,071 
Years Active: 2003-2026
Areas of Expertise:
Title: Thomas D. Bannister: Innovator in Monocarboxylate Transporter Inhibitors
Introduction: Thomas D. Bannister, based in Palm Beach Gardens, Florida, is a prolific inventor with 23 patents to his name. His groundbreaking work primarily focuses on the development of inhibitors targeting monocarboxylate transporters, which hold significant potential in treating serious medical conditions such as cancer and type II diabetes.
Latest Patents: Among Bannister's latest innovations are two notable patents. The first is for heterocyclic inhibitors of monocarboxylate transporters, aimed at providing compounds that effectively inhibit MCT1 and MCT4. These compounds can be instrumental in treating conditions marked by increased activity of these transporters. The second patent revolves around pteridine dione monocarboxylate transporter inhibitors, which showcases his inventiveness in developing compounds that have antitumor, anti-diabetes, anti-inflammatory, and immunosuppressive effects. Both patents signify substantial advancements in the pharmacological treatment of critical health issues.
Career Highlights: Throughout his career, Thomas has made significant contributions to the field of biomedical research. He has been associated with esteemed organizations such as Sepracor, Inc., which is recognized for its innovative approaches to pharmaceuticals, and The Scripps Research Institute, renowned for its cutting-edge scientific discoveries. His work in these environments has amplified his experience and expertise in the development of therapeutic innovations.
Collaborations: Collaboration has been a key aspect of Bannister's success. He has worked alongside notable colleagues, including Brian M. Aquila and Gregory D. Cuny. These partnerships have fostered an environment of creativity and innovation, facilitating the development of advanced therapeutic compounds.
Conclusion: Thomas D. Bannister's contributions to the field of monocarboxylate transporter inhibitors demonstrate his dedication to advancing medical treatments. With a strong patent portfolio and extensive collaboration with industry experts, he continues to make impactful strides in addressing critical health conditions such as cancer and type II diabetes. His innovative spirit positions him as a key figure in the realm of pharmaceutical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile